2-溴-1,4-二甲基-1H-咪唑 | 235426-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-溴-1,4-二甲基-1H-咪唑
• 中文别名: 2-溴-1,4-甲基-1H-咪唑；2-溴-1,4-二甲基咪唑
• 英文名称: 2-bromo-1,4-dimethyl-1H-imidazole
• 英文别名: 2-bromo-1,4-dimethylimidazole
• CAS: 235426-30-9
• 化学式: C₅H₇BrN₂
• 分子量: 175.028
• InChiKey: JKVMBWITGAWCIG-UHFFFAOYSA-N

物化性质

• 熔点：
  46-50
• 沸点：
  253.6±33.0 °C(Predicted)
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933290090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-1,4-dimethyl-1H-imidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-1,4-dimethyl-1H-imidazole
CAS number: 235426-30-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H7BrN2
Molecular weight: 175.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-1,4-二甲基-1H-咪唑 生成 2-bromo-1,4-dimethyl-5-nitro-1H-imidazole
  参考文献：
  名称：

  Langenbeck, Journal fur praktische Chemie (Leipzig 1954), 1928, vol. <2> 119, p. 79

  摘要：

  DOI：
• 作为产物：
  描述：

  1,4 - 二甲基- 1H -咪唑 在 溴化氰 作用下， 以 乙腈 为溶剂， 以29%的产率得到2-溴-1,4-二甲基-1H-咪唑
  参考文献：
  名称：

  Reaction of Imidazoles with Cyanogen Bromide: Cyanation at N 1 or Bromination at C 2?

  摘要：

  一些咪唑（1H-、1-甲基-、2-甲基-、4-甲基-、1,2-、1,4-和 1,5-二甲基-、1-乙基-、1-苄基-和 1-丁基-咪唑）在乙腈溶液中发生反应、和 1-丁基咪唑）以及咪唑与 BrCN 的络合物（[Co(NH3)5(imH)](ClO4)3、[Co(NH3)5(im)](ClO4)2 和[Co(NH3)5(1-Meim)](ClO4)3）进行了研究。带有 N-烷基取代基和 C2 位有氢的咪唑反应生成 2-溴产物，而 N-H-咪唑反应生成 N-氰基衍生物。1,2-二甲基咪唑与 BrCN 反应生成的产物无法定性。在这些复合物中，只有[Co(NH3)5(im)](ClO4)2 发生反应，生成 2-溴产物。我们的观察结果表明，咪唑与 BrCN 反应需要环氮原子上的孤对子，并提出了一种可能的机理。报告了 2-甲基咪唑-1-甲腈的 X 射线结构。晶体数据（-143°C）为 C5H5N3：单斜，P21/c，a10-201(5), b 7-110(3), c 7-227(3) Å, β 100-47(2)°, V 515-4(4) Å 3, Z 4, dcalcd 1-380 gcm¯3 。对所有 1278 个数据的细化结构收敛于 Fo >4F(Fo) 的 1183 次反射的 R1 0-0444 和 wR2 0-1259。

  DOI：

  10.1071/c98105

文献信息

• Site-Selective Thiolation of (Multi)halogenated Heteroarenes
  作者：Frederik Sandfort、Tobias Knecht、Tobias Pinkert、Constantin G. Daniliuc、Frank Glorius

  DOI：10.1021/jacs.0c01630

  日期：2020.4.15

  complementing established methodologies such as nucleophilic aromatic substitution or palladium-catalyzed coupling reactions. Experimental and computational studies suggest a radical chain mechanism with the key step being a homolytic aromatic substitution of the heteroaryl halide by an electrophilic thiyl radical, highlighting an underdeveloped reactivity mode of these radicals.

  报告了各种药物相关的富电子杂芳烃与硫醇的位点选择性硫醇化的一般和简单策略。这种温和而可靠的光催化协议能够在（多）卤化底物的最富电子位置进行 CS 耦合，补充已建立的方法，如亲核芳香取代或钯催化的耦合反应。实验和计算研究表明了一种自由基链机制，其关键步骤是杂芳基卤化物被亲电硫基自由基的均裂芳族取代，突出了这些自由基的不发达反应模式。
• [EN] PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS<br/>[FR] PURINONES UTILISÉS COMME INHIBITEURS DE LA PROTÉASE SPÉCIFIQUE DE L'UBIQUITINE 1
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2017087837A1

  公开（公告）日：2017-05-26

  The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: (I), where R1, R2, R3, R3', R4, R5, X1, X2, X3, X4, and n are described herein.

  该应用涉及对USP1的抑制剂，用于治疗癌症和其他与USP1相关的疾病和紊乱，其化学式为：(I)，其中R1、R2、R3、R3'、R4、R5、X1、X2、X3、X4和n如本文所述。
• [EN] BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS<br/>[FR] DÉRIVÉS DE BENZOXAZINONE AGISSANT COMME AGONISTE DES RÉCEPTEURS BÊTA2-ADRÉNERGIQUES POUR LE TRAITEMENT DE TROUBLES RESPIRATOIRES
  申请人：ASTRAZENECA AB

  公开号：WO2009154557A1

  公开（公告）日：2009-12-23

  The present invention provides a compound of formula (I), wherein W, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了一种化合物，其化学式为（I），其中W、R1、R2和R3如规范中所定义，以及它们的制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• [EN] TYK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
  申请人：NIMBUS LAKSHMI INC

  公开号：WO2018075937A1

  公开（公告）日：2018-04-26

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。
• Development of <b>VU6019650</b>: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M₅ Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder
  作者：Aaron T. Garrison、Douglas L. Orsi、Rory A. Capstick、David Whomble、Jinming Li、Trever R. Carter、Andrew S. Felts、Paige N. Vinson、Alice L. Rodriguez、Allie Han、Krishma Hajari、Hyekyung P. Cho、Laura B. Teal、Madeline G. Ragland、Masoud Ghamari-Langroudi、Michael Bubser、Sichen Chang、Nathalie C. Schnetz-Boutaud、Olivier Boutaud、Anna L. Blobaum、Daniel J. Foster、Colleen M. Niswender、P. Jeffrey Conn、Craig W. Lindsley、Carrie K. Jones、Changho Han

  DOI：10.1021/acs.jmedchem.2c00192

  日期：2022.4.28

  acetylcholine receptor (mAChR) subtype 5 (M5) represents a novel potential target for the treatment of multiple addictive disorders, including opioid use disorder. Through chemical optimization of several functional high-throughput screening hits, VU6019650 (27b) was identified as a novel M5 orthosteric antagonist with high potency (human M5 IC50 = 36 nM), M5 subtype selectivity (>100-fold selectivity against

  毒蕈碱性乙酰胆碱受体 (mAChR) 亚型 5 (M 5 ) 代表了治疗多种成瘾性疾病（包括阿片类药物使用障碍）的新型潜在靶点。通过对几个功能性高通量筛选命中的化学优化，VU6019650 ( 27b ) 被确定为一种新型 M 5正构拮抗剂，具有高效力（人类 M 5 IC 50 = 36 nM）、M 5亚型选择性（对 100 倍以上的选择性） human M 1-4 ) 和在临床前成瘾模型中全身给药的有利物理化学特性。在急性脑切片电生理学研究中，27b阻断了非选择性毒蕈碱激动剂 oxotremorine-M 诱导的腹侧被盖区中脑多巴胺神经元神经元放电率的增加，这是中脑边缘多巴胺能奖励回路的一部分。此外，27b还在不损害一般运动输出的剂量范围内抑制雄性 Sprague-Dawley 大鼠的羟考酮自我给药。